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a b s t r a c t
Aim: To compare the measured and calculated individual and composite ﬁeld planar dose
distribution of Intensity Modulated Radiotherapy plans.
Materials and methods: The measurements were performed in Clinac DHX linear accelera-
tor with 6MV photons using Matrixx device and a solid water phantom. The 20 brain tumor
patients were selected for this study. The IMRT plan was carried out for all the patients using
Eclipse treatment planning system. The veriﬁcation plan was produced for every original
plan using CT scan of Matrixx embedded in the phantom. Every veriﬁcation ﬁeld was mea-
sured by the Matrixx. The TPS calculated and measured dose distributions were compared
for individual and composite ﬁelds.
Results and discussion: The percentage of gamma pixel match for the dose distribution pat-
terns were evaluated using gamma histogram. The gamma pixel match was 95–98% for 41
ﬁelds (39%) and 98% for 59 ﬁelds (61%) with individual ﬁelds. The percentage of gamma pixel
match was 95–98% for 5 patients and 98% for other 12 patients with composite ﬁelds. Three
patients showed a gamma pixel match of less than 95%. The comparison of percentage
gamma pixel match for individual and composite ﬁelds showed more than 2.5% variation
for 6 patients,more than 1% variation for 4 patients, while the remaining 10 patients showed
less than 1% variation.
Conclusion: The individual and composite ﬁeld measurements showed good agreement withTPS calculated dose distribution for the studied patients. The measurement and data anal-
ysis for individual ﬁelds is a time consuming process, the composite ﬁeld analysis may be
sufﬁcient enough for smaller ﬁeld dose distribution analysis with array detectors.
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1. Background
Intensity modulated ﬁelds have the potential to deliver opti-
mum dose distributions which results in a greater dose
uniformity in the target and lower doses to the neighboring
critical organs and normal healthy structures as compared
to conventional external beams employing wedges and cer-
roband blocks.1 The clinical implementation of Intensity
Modulated Radiotherapy (IMRT) requires special commission-
ing procedures including machine and patient-related routine
quality assurance (QA).2–8 The IMRT has made a considerable
impact on both clinical and physical aspects of radiother-
apy. The IMRT patient speciﬁc QA procedures have been
emphasized and the clinical requirements for IMRT imple-
mentation have been the driving force behind many medical
physics research activities. A major difﬁculty with designing
IMRT QA procedures for treatment delivery units, treatment
planning system (TPS) and patient-speciﬁc QA was that the
likely failures for this new treatment technique were not
known. On the other hand, traditionally used methods and
equipment designed for dose veriﬁcation in uniform inten-
sity beams were becoming obsolete. For example, point dose
measurements were replaced or supplemented with two-
dimensional measurements.9,10 Another example is monitor
unit (MU) veriﬁcation procedures, as empirical methods for
dose calculation11 cannot be applied or extended to IMRT in
any straightforward manner. Due to the lack of efﬁcient tools
for patient-speciﬁc QA, routine dosimetric methods are still
commonly used to verify IMRT treatment plans.12 The Euro-
peanSociety for Therapeutic RadiationOncology (ESTRO) have
started theQUASIMODO (QUalityASsuranceof IntensityMOD-
ulated radiation Oncology) network between ﬁfteen European
centers.13 They suggest that the veriﬁcation of a composite
plan is of utmost importance for the actual patient treatment.
Agazaryan et al.14 compared the measured single ﬁeld and
composite ﬁeld IMRT planar dose with TPS computed values.
2. Aim
The patient speciﬁc IMRT QA of brain tumor patients were
carried out using a 2-D ion chamber array detector. The planar
dosedistributionmeasuredby the arraydetector for individual
and composite ﬁeld were compared with the TPS calculated
dose distribution.
3. Materials and methods
The Matrixx (Matrixx, IBA Dosimetry GmBH, Schwarzenbruck,
Germany) device consists of 1020 vented ion chamber array
detectors, arranged in 32×32 grid. Eeach chamber volume is
0.08 cm3 with the height of 5mm and diameter of 4.5mm.
The detecting system can measure the dose distribution for
the dose rate ranging from 0.1Gy/min to 5Gy/min.15 The bias
voltage required for the Matrixx system is 500±30V. The
equivalent absorber thickness on the front side of thematrix is
3.6mm. The maximum ﬁeld of view is 24×24 cm2. Before the
measurement, the device requires 15min of warm-up time.
The device runs with two separate counters to avoid deadFig. 1 – Matrixx along with slap phantom.
time, the minimum sampling period is 20ms. The Matrixx
device can be directly connected to PC via standard ethernet
interface to acquire the measured charge.
The measurements were performed on Clinac DHX lin-
ear accelerator with 6MV photon beams using Matrixx device
and a RW3 solid water phantom. The Millennium multileaf
collimator (MLC) is an accessory attached to the treatment
head below the secondary jaws as tertiary collimator. The Mil-
lennium MLC contains 120 leaves designed with 5mm leaf
width projected at isocenter the middle 20 cm of the treat-
ment ﬁeld and 10mm leaf width projected over the peripheral
10 cm on each side of the treatment ﬁeld. The leaf movements
are controlled by the stepper motors through MLC controller
workstation (Millennium MLC user guide, P/N 100011548).
The MLC is capable of producing irregular shaped ﬁelds and
dynamic motion. It is possible to achieve dose dynamic and
arc dynamic IMRT treatments with dynamic MLC motion. The
Matrixx device with a 5 cm solid water phantom positioned
above and below was scanned with 2mm CT slice thickness.
The CT scan data was imported to TPS for 3-D reconstruction
and planning. Twenty brain tumor patients were selected for
this study. The IMRT treatment plan was carried out for all
the patients using the sliding window technique with Eclipse
treatment planning system (Varian Medical systems, USA).
The 5 equally spaced beam angles were selected for each plan
at an interval of 72◦ for all the brain tumor patients. The
Anistrophic analytical algorithm (AAA) was used with the cal-
culation grid size of 2.5mm for dose computation. The IMRT
optimization was carried out using Dose Volume Optimizer
(DVO) algorithm within the Eclipse treatment planning sys-
tem. In order to verify an IMRT plan a veriﬁcation plan with
the gantry and collimator angles set at 0 degreeswas produced
for every original plan using CT scan data of Matrixx device.
The CT data of the measurement system was used to estimate
the dose distribution at depth for these veriﬁcation plans. The





















dFig. 2 – Comparison of measured and cal
eriﬁcation plan was exported to the detector system with the
etector plane positioned at isocenter. The gantry and col-
imator angles were set at 0 degrees. The central beam was
ade perpendicular to the Matrixx measurement level at the
enter of the measurement area. The Matrixx setup is shown
n Fig. 1. Every veriﬁcation ﬁeld was exported to the accelera-
or console and the same was delivered and measured by the
atrixx device. The TPS calculated individual and compos-
te ﬁeld dose distributions were transferred to OmniPro IMRT
oftware for comparison. The measured Matrixx signal for
ach ﬁeld was post-processed with linear interpolation using
.2mm grid. The same grid value was selected for TPS calcu-
ated dose distribution pattern for comparison. The measured
ndividual dose distribution was compared with TPS calcu-
ated dose distribution and the percentages of pixel match
alues were evaluated using gamma histogram.
. Results and discussionhe measured and calculated dose distribution patterns were
mported to OmniPro IMRT software workspace for analysis in
ata set 1 and data set 2. The gamma criteria were set at 3%
Fig. 3 – (a) and (b) Compared proﬁle along thted dose distribution for individual ﬁeld.
dose difference and 3mm distance-to-agreement (DTA) with
 ≤1. Fig. 2 shows the comparison of measured and calculated
planar dose distribution for an individual ﬁeld. The compared
proﬁle along the X and Y directions for an individual ﬁeld is
shown in Fig. 3a and b. Fig. 4 shows the compared isodose
distribution of an individual ﬁeld. The percentage of gamma
pixel match for an individual ﬁeld was obtained. The gamma
pixel match was less than 95% for 5 ﬁelds. The gamma pixel
match was between 95 and 98% for 41 ﬁelds (39%) and 59 ﬁelds
(61%) have shown the gamma pixel match of more than 98%.
Similarly, the measured composite dose distribution was
compared with TPS calculated dose distribution and the per-
centages of pixel match values were evaluated using gamma
histogram. Fig. 5 shows the comparison of measured and cal-
culated planar dose distribution for a composite ﬁeld. The
compared proﬁle along the X and Y directions for cumula-
tive ﬁeld is shown in Fig. 6a and b. Fig. 7 shows a typical
compared isodose distribution for a composite ﬁeld. The per-
centage of gamma pixel match was 95–98% for 5 patients and
12 patients showed the gamma pixel match of more than 98%
for a composite ﬁeld. The gamma pixel match of less than 95%
was noticed only for 3 patients. The root mean square (RMS)
values were calculated for an individual ﬁeld gamma pixel
e X and Y directions for individual ﬁeld.
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Table 1 – Percentage of points passing the gamma criteria of 3%/3mm for composite and individual plan analysis for
head and neck patients.
Field (Gantry angle) Percentage of points passing the gamma criteria of 3%/3mm
Patient 1 Patient 2 Patient 3
0◦ 92.29% 99.21% 92.17%
40◦ 97.14% 96.59% 94.05%
80◦ 99.67% 93.49% 99.20%
120◦ 83.61% 97.05% 98.33%
160◦ 98.39% 91.87% 91.80%
280◦ 96.50% 95.70% 94.57%
320◦ 91.74% 99.34% 99.38%
200◦ 96.18% 98.53%
240◦ 94.06% 98.22%
Composite ﬁeld 91.69% 91.51%
Fig. 4 – Compared isodose distribution for individual ﬁeld. composite and individual plan analysis is shown in Table 1.Fig. 5 – Comparison of measured and calcula94.64%
99.20%
90.70%
match of each patient. The gamma pixel match of 95–98% was
shown for 10 patients and 10 patients were shown the gamma
pixel match of more than 98%. Fig. 8 shows the comparison
of percentage gamma pixel match values for individual and
composite ﬁelds. Six patients were noticed to show more than
2.5% variation between individual and composite ﬁeld analy-
sis and 4patients have shownmore than 1%variation between
the individual and composite ﬁeld analysis. The remaining 10
patients showed less than 1%variation between the individual
and composite ﬁeld analysis. The AAPM TG119 recommends
that the percentage of the gamma criteria should be more
than 88% for an individual ﬁeld analysis and 93% for com-
posite ﬁelds.16 The results in our study are in good agreement
with the AAPM TG119 recommendation. It was observed that
for smaller targets to be treated, like brain, the composite ﬁeld
analyses are not much different from an individual analysis.
In case of large targets, like Head and Neck, the magnitude of
deviation between individual and composite ﬁelds was also
analyzed for 3 head and neck patients. The results of per-
centage of points passing the gamma criteria of 3%/3mm forThe gamma pixel match varied from 83.6% to 99.7% for indi-
vidual ﬁelds and 90–92% for composite ﬁelds.
ted dose distribution for composite ﬁeld.
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Fig. 6 – (a) and (b) Compared proﬁle along the
Fig. 7 – Compared isodose distribution for composite ﬁeld.Fig. 8 – Comparison of percentage gamma pixel maX and Y directions for composite ﬁeld.
5. Conclusion
The IMRT plans were analyzed by comparing measured and
calculated dose distributions for both composite and individ-
ual ﬁelds. Both individual and composite ﬁeld measurements
showed good agreement with TPS calculated dose distribu-
tion for the studied patients. Although the composite ﬁeld
analysis, the cumulative dose distribution, the magnitude of
deviation with some beam angles could be suppressed when
combined with the other ﬁelds. The individual ﬁeld delivery
permits the beam’s delivery to be analyzed in detail but does
not assure that the beams combine appropriately. Hence, for
the smaller tumors, like brain, the composite ﬁeld analysis are
not much different from individual analysis, whereas for large
tumors, the magnitude of deviation between individual and
composite ﬁeld analysis may be higher due to doses added
together from the larger area. In case of large ﬁeld compos-
ite analysis, it may not be possible to predict by which ﬁeld
the maximum deviation in dose delivery occurs. As the mea-tch values for individual and composite ﬁelds.
surement and data analysis for individual ﬁelds are a time
consuming process, the composite ﬁeld analysis may be sufﬁ-
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